Abeona Therapeutics Inc

In a Stage 2 advance with clear higher highs and higher lows, price has broken above a key pivot but is currently extended and overbought. Speculative engagement should be deferred until a pullback into the rising EMA 9/21/50 cluster confirms support.

• ↑PZ-Cell therapy projects U.S. revenue potential exceeding $2B (≥$1.5M/treatment).
• ↑Cash increased to $98.1M vs. $52.6M YoY, securing funding into 2026.
• ↓Net loss of $63.7M in 2024 and negative profitability factors signal weakness.